AstraZeneca

AstraZeneca completed studies supporting regulatory filings for Breztri/Trixeo Aerosphere transition to a next-gen propellant with 99.9% lower Global Warming Potential. Breztri, a COPD therapy, will be the first in AstraZeneca's pMDI portfolio to use this propellant, with clinical programs for wider portfolio transition underway. Studies results will be shared with regulatory authorities, with submissions expected in Europe, UK, and China by end of 2024.

Innate Pharma announced AstraZeneca's interim NeoCOAST-2 Phase 2 study results at the 2024 World Conference on Lung Cancer, showing promising efficacy and safety profiles for monalizumab in early-stage NSCLC.

AstraZeneca presented interim results from the NeoCOAST-2 Phase 2 study at the 2024 World Conference on Lung Cancer, showing promising outcomes for early-stage non-small cell lung cancer patients across treatment arms. Monalizumab, in combination with durvalumab and platinum-based chemotherapy, demonstrated higher pathological complete response and major pathological response rates compared to the approved regimen, with a manageable safety profile.

TROPION-Lung01 Phase III trial results show TROP2, measured by AstraZeneca's QCS, predicts clinical outcomes in advanced NSCLC patients treated with datopotamab deruxtecan (Dato-DXd), demonstrating greater efficacy in TROP2-QCS positive tumors compared to docetaxel.

ESMO 2024 in Barcelona will feature discussions on cancer therapeutics, including anticipated presentations on bispecific antibodies and anti-TIGIT therapies. Other topics include radioligand therapies and synthetic lethality assets. Experts are optimistic about the potential of these therapeutic classes, despite past challenges.

The Orphan Drugs Market is projected to grow from USD 225.9 Billion in 2023 to USD 493.21 Billion by 2031, driven by rising prevalence of rare diseases, unmet medical needs, favorable regulatory policies, technological advancements, and growing public and patient advocacy. Key challenges include high R&D costs, limited patient populations, pricing and reimbursement issues, and lack of long-term data. Trends include focus on gene therapies, personalized medicine, stakeholder collaboration, and expansion into emerging markets. North America leads the market, followed by Europe and Asia Pacific.

Prostate Cancer Treatment Market growth driven by rising incidence, awareness, and advances in technologies like immunotherapy and targeted biologics. Market expected to grow at 5.00% CAGR from 2024 to 2031, supported by healthcare infrastructure investments and personalized medicine.

FPI-2265, a radionuclide targeting prostate specific membrane antigen (PSMA) for metastatic prostate cancer, is expected to generate $202 mn in annual revenue by 2035 in the US. Fusion Pharmaceuticals, a subsidiary of AstraZeneca, develops this intravenous therapy. The risk-adjusted NPV (rNPV) model, which considers drug failure risk, is used for valuation.

TROP2 biomarker, measured by AstraZeneca's QCS, predicts clinical outcomes in NSCLC patients treated with datopotamab deruxtecan in TROPION-Lung01 trial, showing greater efficacy in TROP2-QCS positive tumors. AstraZeneca and Roche collaborate to develop a TROP2-QCS companion diagnostic.